SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-23-052742
Filing Date
2023-11-13
Accepted
2023-11-13 08:30:44
Documents
76
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ef20012432_10q.htm   iXBRL 10-Q 1589655
2 EXHIBIT 31.1 ef20012432_ex31-1.htm EX-31.1 6599
3 EXHIBIT 31.2 ef20012432_ex31-2.htm EX-31.2 6621
4 EXHIBIT 32.1 ef20012432_ex32-1.htm EX-32.1 3983
5 EXHIBIT 32.2 ef20012432_ex32-2.htm EX-32.2 3974
11 image00007.jpg GRAPHIC 2588
  Complete submission text file 0001140361-23-052742.txt   7198864

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA erna-20230930.xsd EX-101.SCH 63319
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE erna-20230930_cal.xml EX-101.CAL 64111
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE erna-20230930_def.xml EX-101.DEF 293068
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20230930_lab.xml EX-101.LAB 757280
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20230930_pre.xml EX-101.PRE 449006
70 EXTRACTED XBRL INSTANCE DOCUMENT ef20012432_10q_htm.xml XML 935458
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-11460 | Film No.: 231395415
SIC: 2834 Pharmaceutical Preparations